100% secure
bookmark this page

B Cells Antibody | FMC7

//www.bio-rad-antibodies.com/human-b-cells-antibody-fmc7-mca792f.html?RenderPageSpecific=1
B Cells Antibody | FMC7 gallery image 1

Staining of human peripheral blood lymphocytes with Mouse anti Human B-Cells : FITC (MCA792F)

Enlarge
  • B Cells Antibody | FMC7 thumbnail image 1
  • Mouse anti Human B Cells:FITC

(write a review)

(Rated 0.0 out of 5 based on 0 customer reviews)
  • Product Type
    Monoclonal Antibody
  • Clone
    FMC7
  • Isotype
    IgM
1 Formats Available
    Product CodeApplicationsDatasheetMSDSPack SizeList PriceQuantity
    MCA792FFdatasheet pdfdatasheet pdf100 Tests/1ml
    MCA792F
    Summary
    Secondary Antibodies
    Negative Isotype Controls
    Useful Reagents
    Positive Controls
    Histology Controls
    More Images
    References
    Reviews
    -
    • Mouse anti Human B cells antibody, clone FMC7 recognizes a glycoprotein antigen of ~105 kDa expressed by B lymphocytes. The FMC7 antigen is expressed by peripheral B lymphocytes, and has been used widely in the study of B cell malignancy. Mouse anti Human B cells antibody, clone FMC7 has been used extensively to differentiate various types of B cell malignancy. B-CLL is generally considered to be negative for FMC7 expression, but strong staining is seen in many other types of B cell lymphoma, including prolymphocytic leukaemia and hairy cell leukaemia.

      The nature of the FMC7 antigen has remained poorly defined following its first description in 1981. The expression pattern closely corresponds to that seen with CD22, but studies have shown that FMC7 does not recognise the CD22 molecule itself. Mouse anti Human B cells antibody, clone FMC7 recognizes a conformational epitope on the CD20 molecule, most likely a multimeric complex of CD20 (Serke et al. 2001). Identity of CD20 as the antigen recognized by Mouse anti Human B cells antibody, clone FMC7 was further confirmed by strong recognition of recombinant CD20 expressed in hematopoietic and non-hematopoietic cell lines and abolishion of binding in CD20 extracellular domain mutations. The recognized epitope has also been shown to be cholesterol dependent (Polyak et al. 2003).
    • Intended Use
    • Target Species
      Human
    • Product Form
      Purified IgM conjugated to Fluorescein Isothiocyanate Isomer 1 (FITC) - liquid
    • Reconstitution
    • Preparation
      Purified IgM prepared by gel filtration
    • Preservative Stabilisers
      0.1% Sodium Azide (NaN3)
      0.2% Bovine Serum Albumin
    • Immunogen
      HRIK cells - Human B-Lymphoblastoid line.
    • Purity
    • Approx. Protein Concentrations
    • Reagents In The Kit
    • Preparing The Antibody
    • Test Principle
    • Buffer Solution
      TRIS buffered glycine
    • Storage
      Store at +4oC or at -20oC if preferred.
      Storage in frost-free freezers is not recommended.
      This product should be stored undiluted. This product is photosensitive and should be protected from light.
      Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
    • Shelf Life
      18 months from date of despatch.
    • GO Terms
      GO:0042113
      B cell activation
      Related reagents
      GO:0006955
      immune response
      Related reagents
      GO:0005887
      integral to plasma membrane
      Related reagents
    • UniProt
    • Entrez Gene
    • Acknowledgements
    • Regulatory
      For research purposes only
    • This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.

    • Application NameYesNoMin DilutionMax Dilution
      Flow CytometryNeat

    • Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
    • Technical Advice
    • Recommended Protocol
    • Flow Cytometry
      Use 10ul of the suggested working dilution to label 106 cells or 100ul whole blood.
    • ELISA
    • Immunohistology
    • Histology Positive Control Tissue
    • Immunofluorescence
    • Western Blotting
    • Instructions For Use

    Additional B Cells Antibody Formats

    Formats Clone Applications Sizes available
    B Cells Antibody : FITC FMC7 F 100 Tests/1ml
    • Copyright © 2018 Bio-Rad Antibodies (formerly AbD Serotec)

    Recommended Secondary Antibody

      Recommended Negative Isotype Control

        DescriptionProduct CodePack SizeApplicationsList PriceQuantity
        Mouse IgM Negative Control:FITCMCA692F0.1 mgF
        MCA692F

        Useful Reagents

          DescriptionProduct CodePack SizeApplicationsList PriceQuantity
          Human SeroblockBUF070B200 TestF
          BUF070B
          Human SeroblockBUF070A50 TestF
          BUF070A

          Recommended Positive Controls

            Histology Controls

              Source Reference

              1. Brooks, D.A. et al. (1981) Human lymphocyte markers defined by antibodies derived from somatic cell hybrids. IV. A monoclonal antibody reacting specifically with a subpopulation of human B lymphocytes.
              J Immunol. 126 (4): 1373-7.

              References

              1. Catovsky, D. et al. (1981) Heterogeneity of B-cell leukemias demonstrated by the monoclonal antibody FMC7.
              Blood. 58 (2): 406-8.
              2. Serke, S. et al. (2001) Monoclonal antibody FMC7 detects a conformational epitope on the CD20 molecule: Evidence from phenotyping after Rituxan therapy and transfectant cell analyses.
              Cytometry (Comm. Clin. Cytometry) 46:98-104
              4. Zola, H. et al. (1984) The antigen of mature human B cells detected by the monoclonal antibody FMC7: studies on the nature of the antigen and modulation of its expression.
              J Immunol. 133 (1): 321-6.
              5. Bloem, A.C. et al. (1988) Functional properties of human B cell subpopulations defined by monoclonal antibodies HB4 and FMC7.
              J Immunol. 140 (3): 768-73.
              6. Zola, H. et al. (1987) Markers of differentiated B cell leukaemia: CD22 antibodies and FMC7 react with different molecules.
              Dis Markers. 5 (4): 227-35.
              7. Ghia, P. et al. (2003) The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression.
              Blood. 101 (4): 1262-9.
              8. Ferro LM & Zola H (1990) Modulation of expression of the antigen identified by FMC7 upon human B-lymphocyte activation: evidence for differences between activation in vivo and in vitro.
              Immunology. 69 (3): 373-8.
              10. Zucchetto A et al. (2006) A scoring system based on the expression of six surface molecules allows the identification of three prognostic risk groups in B-cell chronic lymphocytic leukemia.
              J Cell Physiol. 207 (2): 354-63.
              11. Wang, C. et al. (2002) Differentiation of monoclonal B lymphocytosis of undetermined significance (MLUS) and chronic lymphocytic leukemia (CLL) with weak CD5 expression from CD5(-) CLL.
              Leuk Res. 26 (12): 1125-9.
              12. Amato, D. et al. (2007) Cytogenetic aberrations and immunoglobulin VH gene mutations in clinically benign CD5- monoclonal B-cell lymphocytosis.
              Am J Clin Pathol. 128 (2): 333-8.
              13. Polyak, M.J. et al. (2003) A cholesterol-dependent CD20 epitope detected by the FMC7 antibody.
              Leukemia. 17 (7): 1384-9.
              14. Domingo-Domènech, E. et al. (2002) CD38 expression in B-chronic lymphocytic leukemia: association with clinical presentation and outcome in 155 patients.
              Haematologica. 87 (10): 1021-7.
              15. Gladkikh, A. et al. (2010) Cyclin D1 expression in B-cell lymphomas.
              Exp Hematol. 38 (11): 1047-57.
              16. Unruh, T.L. et al. (2005) Cholesterol depletion inhibits src family kinase-dependent calcium mobilization and apoptosis induced by rituximab crosslinking.
              Immunology. 116 (2): 223-32.
              17. Gladkikh, A.A. et al. (2017) Comparison of the mRNA expression profile of B-cell receptor components in normal CD5-high B-lymphocytes and chronic lymphocytic leukemia: a key role of ZAP70.
              Cancer Med. 6 (12): 2984-97.

              Write your review
              Sign-up to receive our eNewsletters
              • View more products with "B CELLS" specificity.

              You may also be interested in...